S-1: Know Labs Files for Resale of Up to 10.8 Million Shares of Common Stock

Know Labs has filed a registration statement for the potential resale of up to 10.8 million shares of its common stock by a selling stockholder.

Summary

• Know Labs has filed a Form S-1 registration statement with the SEC relating to the resale of up to 10,800,000 shares of its common stock.
• The shares are to be offered by a selling stockholder and consist of shares issuable upon conversion of a secured convertible note and shares underlying a common stock purchase warrant.
• Know Labs will not receive any proceeds from the sale of these shares by the selling stockholder.
• The company's common stock is listed on the NYSE American under the symbol KNW, and the closing price on March 25, 2024, was $0.65 per share.
• The selling stockholder may be considered an underwriter and may sell shares at prevailing market prices or in privately negotiated transactions.
• The company is focused on developing and commercializing its proprietary sensor technology for non-invasive medical diagnostics, with an initial application in blood glucose monitoring.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focused on disclosing information about the share resale. The lack of company proceeds and potential stock price pressure are balanced by the company's ongoing development efforts.

Positives

• The registration allows the selling stockholder to sell shares in the public market, potentially increasing liquidity.
• Know Labs is not issuing new shares or receiving proceeds, so there is no immediate dilution to existing shareholders from this filing.

Negatives

• The potential sale of a large number of shares by the selling stockholder could put downward pressure on the stock price.
• The company will not receive any proceeds from the sale of shares by the selling stockholder.

Risks

• The selling stockholder may be deemed an underwriter, which could create regulatory scrutiny.
• The market price of Know Labs' common stock is volatile, and sales by the selling stockholder could exacerbate this volatility.
• The company's ability to maintain its listing on the NYSE American is contingent on meeting certain requirements, including share price and equity standards.
• The company has a history of operating losses and may need additional financing to continue operations.

Future Outlook

Know Labs plans to expand its sensor technology to other non-invasive medical diagnostic applications following FDA clearance of its non-invasive blood glucose monitoring device.

Industry Context

The company operates in the competitive medical diagnostics industry, particularly in the blood glucose monitoring market, where it faces competition from established players and new entrants developing non-invasive solutions.

Comparison to Industry Standards

• Know Labs is developing a non-invasive glucose monitor to compete with existing continuous glucose monitoring (CGM) systems from companies like DexCom and Abbott Labs.
• The company claims its technology addresses the limitations of non-invasive optical technologies, which can be affected by skin tones.
• Know Labs states that it is the world intellectual property leader in non-invasive blood glucose monitoring, according to ipCG Capital and PatSnap.

Stakeholder Impact

• Shareholders may experience stock price volatility due to potential sales by the selling stockholder.
• The company's employees and customers are not directly impacted by this filing, but their interests are tied to the company's long-term success in developing and commercializing its technology.

Next Steps

• The selling stockholder may sell the shares from time to time.
• Know Labs will continue to develop and refine its non-invasive blood glucose monitoring device and pursue FDA clearance.

Key Dates

Keywords

common stock, resale, registration statement, convertible note, stock warrant, selling stockholder, KNW, non-invasive glucose monitoring, medical diagnostics, Know Labs